Sanofi raises estimates for 2021: net profit to 2.3 billion, up 19%
Not just Covid vaccines, the French pharmaceutical group Sanofi sees the numbers shine thanks to flu vaccines, which drive growth of 25%, to 1.3 billion. The group has indeed revised its estimates for 2021 are up after that in the third quarter net profit of group reached i 2.3 billion euros, up by almost 19% in a year. The Operating income recorded a similar increase of 2.7 billion, against a turnover of more than 10.4 billion. Net profit per share is rose by more than 19% to 2.18 euros.
Sanofi, who had already raised his forecast in July, now expects eps to grow 14% at constant exchange rates this year, up from 12% initially announced. Among the various sectors of activity, the branch of medical specialties continues to drive growth (+ 20.2%) to around 3.3 billion euros. Vaccines also recorded a record increase of 16.5% to over 2.4 billion euros, driven in particular by flu vaccines (+ 25.5% to 1.3 billion euros). Finally, the turnover of the “general public health” division increased by over 11% to 1.1 billion euros.
“I Sanofi’s third quarter financial results are excellent, he has declared Paul Hudson, general manager of Sanofi. “Our sales have seen double-digit growth driven by Dupixent’s remarkable performance, record vaccine sales and the dynamism of the Consumer Healthcare business, in line with our strategic priorities,” Hudson said.
“As a result, we have revised up our forecast for corporate EPS growth to around 14% for the current year. Our research and development portfolio of innovative therapeutic solutions has continued to grow. In particular, I will mention the recent ones positive results of Dupixent in the treatment of eosinophilic esophagitis and prurigo nodularis as well as the approval and launch in the United States of Nexviazyme in the treatment of Pompe disease, “he continued Hudson.
“Through increased investments in research and development and targeted acquisitions of Translate Bio and Kadmon, we further strengthen our commitment to providing patients with innovative treatments and to generate the growth of tomorrow. As part of our social and social commitment e in view of COP 26, we are strengthening our environmental, social and governance (ESG) objectives with the ambitious reduction of our carbon emissions to fight climate change “, concluded Hudson.